Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neurocrine Biosciences
Marketing
Neurocrine joins in on Tardive Dyskinesia Awareness Week
Neurocrine, maker of the first drug approved by the FDA to treat TD, is throwing its weight behind efforts to improve awareness of the disorder.
Andrea Park
May 6, 2024 10:52am
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Apr 26, 2024 5:45am
Neurocrine asks ‘What the C@H?!’ in new hyperplasia campaign
Apr 25, 2024 12:04pm
Neurocrine's Ingrezza nabs Huntington's nod to rival Austedo
Aug 22, 2023 9:53am
Neurocrine gives up on Parkinson's drug Ongentys
May 3, 2023 10:55am
Neurocrine doles out £48M to acquire small UK biotech Diurnal
Aug 30, 2022 11:30am